Supplementary Tables from Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Abstract

Supplementary Table S1. Whole Exome Sequencing (WES) results on crizotinib resistant biopsy. Supplementary Table S2. Single base substitutions leading to ALK and ROS1 kinase domain mutations.